ClinicalTrials.gg
Active, not recruitingNCT06587243Updated Aug 10, 2026

"Facts Tell… and With Stories Sell?" Combining Viewer-tailored Personal Human Papillomavirus (HPV) Narrative Video With HPV Vaccine Information Video to Improve HPV Vaccine Uptake

An interventional study of Informational Animation Video and Personal Narrative Video in Vaccination, sponsored by Johns Hopkins Bloomberg School of Public Health. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-08-10.

Primary conditionNarration(the registry's first term)UnverifiedIs this wrong?Narration is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Johns Hopkins Bloomberg School of Public Health · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Sex
All
01

Study summary

This study will compare the use of informational videos only, personal story videos only, and the combination of both, to see which is most effective in increasing HPV vaccination.

02

Conditions studied

  • Vaccination

Browse trials for

Keywords

  • HPV
  • Vaccine
  • Narrative
  • Communication
  • Videos
03

In context

Narration Unverified

39 studies on the registry are indexed under Narration; 3 are open to participants now.

This study's planned enrollment of 1,100 is above the median of 126 across 29 interventional studies indexed under Narration.

Browse Narration studies →

Lead sponsor

Johns Hopkins Bloomberg School of Public Health is the lead sponsor of 371 studies on the registry; 41 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Compared within Narration, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parents of 11-17 year olds not yet vaccinated against HPV

Exclusion criteria

Exclusion Criteria:

  • Parents whose adolescent children are already vaccinated against HPV
  • Participants who do not complete the survey
  • Participants who are unable or refuse to view and listen to videos on the participant's device
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,100 participants (estimated)

Study arms

  • No intervention
    Control

    No videos

  • Experimental
    Animation Only

    informational animation video only

    Behavioral: Informational Animation Video

  • Experimental
    Narrative Only

    personal narrative video only

    Behavioral: Personal Narrative Video

  • Experimental
    Narrative Then Animation

    personal narrative video followed immediately by the informational animation video

    Behavioral: Informational Animation Video · Behavioral: Personal Narrative Video

  • Experimental
    Animation Then Narrative

    informational animation video followed immediately by the personal narrative video

    Behavioral: Informational Animation Video · Behavioral: Personal Narrative Video

Interventions

  • BehavioralInformational Animation Video

    The informational animation video will also take several minutes and will cover HPV disease, address specific concerns when identified, and the importance and safety of HPV vaccines.

  • BehavioralPersonal Narrative Video

    Personal narrative videos will consist of someone describing the person's own personal experience with HPV. The investigators have a collection of videos of personal narratives from different people that the investigators have cut to approximate several minutes in length so the investigators can tailor the personal narratives to match each study participant's race/ethnicity and gender as closely as possible.

06

What researchers measure

Primary outcomes

  1. Number of participants who receive HPV vaccination

    HPV vaccination will be a binary variable (received vs not received)

    Time frame: 9-month follow-up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Jun 2026, 6 months.

Of 27 non-industry interventional studies with no phase under Narration, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's 6 months is below that.

Counting every sponsor, half of 27 studies reached it within 12 months; a quarter within 6 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2024
First posted
Sep 19, 2024
StartActual
Nov 24, 2025
Primary completionActual
Jun 2, 2026
CompletionEst.
Jan 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06587243
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Nov 24, 2025
Primary completion
Jun 2, 2026
Completion
Jan 2027 (estimated)
Last update
Aug 10, 2026

Study contacts

Daniel Salmon, PhD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion